If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy

$48.00 plus tax (Refund Policy)

Download / Buy Article:


Kurne A, Guc D, Canpinar H, Aydin ÖF, Sayat G, Yörübulut M, Esendagli G, Karabudak R. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy.

Acta Neurol Scand: 2011: 123: 8–12.

© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard. Objectives – 

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and B cell-activating factor (BAFF), the members of tumor necrosis factor superfamily, play essential roles in immune homeostasis and may have potential contributions to the autoimmune process in multiple sclerosis (MS). Material and methods – 

Thirty-five relapsing remitting MS (RRMS) patients and 19 healthy individuals were enrolled in the study. The expression of TRAIL on peripheral blood lymphocytes was analyzed by flow cytometry. The serum levels of soluble TRAIL (sTRAIL) and soluble BAFF (sBAFF) were determined by ELISA. Further, we evaluated the effect of IFN-β on sTRAIL, sBAFF levels and on TRAIL surface expression in these patients on the third and sixth months following the treatment. Results and conclusion – 

These preliminary results signify that MS patients are heterogenous in TRAIL expression. Additionally, during the IFN-β treatment, the soluble form of TRAIL increases concomitantly as its surface expression decreases on lymphocytes. The basal sBAFF levels of patients were significantly higher than the control group and no significant change was observed. Thus, the changes in TRAIL expression may be a potential parameter indicating the response to IFN-β1 therapy at individual level.

Keywords: B cell-activating factor; immunomodulation; interferon 1β therapy; multiple sclerosis; tumor necrosis factor-related apoptosis-inducing ligand

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0404.2010.01346.x

Affiliations: 1: Department of Neurology, Hacettepe University Hospitals, Neuroimmunology Unit, Ankara, Turkey 2: Department of Basic Oncology, Hacettepe University, Institute of Oncology, Ankara, Turkey 3: Department of Pediatric Neurology, Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey 4: Primer Medical Imaging Center, Ankara, Turkey

Publication date: January 1, 2011

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more